Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

It could be an attempt not to use the same verbiage expected to be included in published articles. The US RBL's are unlikely to want to see Leo quoting exactly what they give him. Most publications want info to be new and previously unseen elsewhere.

Just another thought that I see as more likely.





Message in reply to:

I can tell you the issues I have with these specific sentences.

Quote:
"In the RBL assay (which included Brilacidin pre-incubated with virus), Brilacidin exhibited approximately 90 percent inhibition against SARS-CoV-2 at a concentration similar to that of Remdesivir™, which again reported 50 percent inhibition of the coronavirus. The Brilacidin inhibition assay was tested in a human lung epithelial cell line, with Remdesivir™ tested in Vero cells."


Why use the phrase “at a concentration similar to” rather than providing the actual concentration? It implies that there’s something underneath that is not favorable to the writer of the PR.

Why compare results from tests on 2 different cell lines? Was Remdesivir not tested in lung epithelial cell lines? Again, it implies that the lung cell comparison is less favorable to the writer of the PR.

That's what I see.